**Evaluation of Some Biological Parameters and Trace Elements in Prostatic Tumors among Iraqi Patients with DMII**

1Usama Salamn Mahdy AL-AZZAWI, 2Prof. Dr. Volkan EYÜPOĞLU

1 Ministry of Health - Iraq/ Diyala

2 Graduate School of Natural and Applied Sciences - Çankırı Karatekin University/ Turkey- Çankırı

Among the challenges facing doctors in advanced prostate, cancer management is that it is developing quickly, which requires research in rapid ways to predict its development. Our goal in this study is to define some liver tests (Alp), Chloe., PSA, and TPA tests, focus on some trace elements in men with prostate and type 2 diabetes and discover the linear relationship between the specified tracking elements that were estimated between cases. The kidney fears tests were not mentioned in this study, but the levels of uric acid were significantly affected. There was clear importance of liver enzymes, whose levels were clearly affected, and there was a link between them and PSA in prostate cancer patients. The vowed elements did not have great influence, especially magnesium and selenium, on the contrary, zinc had a great statistical and clinical importance in this study. In general, during this study, the necessary parameters will be identified as good indicators for prostate cancer patients and DMII in the same time.

**Keywords:** Prostatic tumors, Trace elements, DMII, PSA, TPA

**REFERENCES**

Hope, T., Goodman, J., Allen, I. Meta-analysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histology. J Nucl Med 2019; 6600: 786.

 Fendler, W., Calais, J., Eiber, M. 2019. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single arm trial. JAMA Oncol 2019 (epub Mar 28).

Calais, J., Ceci, F., Eiber, M. 2019. 18F-fluciclovine PETCT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single arm, comparative imaging trial. Lancet Oncol 2019; 20:1286.

 Decaestecker, K., De, Meerleer G, Ameye F et al: Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 2014;14:671.

Radwan N, Phillips R, Ross A et al: A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). BMC Cancer 2017;17:453.